Search Result

Results for "

hypoxia-inducible factor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HIF/HIF Prolyl-Hydroxylase (85) ADC Payload (3) Akt (5) Antibiotic (16) Apoptosis (24) Autophagy (5) Bacterial (13) Bcl-2 Family (1) Beclin1 (3) Calcium Channel (8) Caspase (2) ERK (1) Estrogen Receptor/ERR (1) Ferroptosis (5) Fungal (3) FXR (1) G protein-coupled Bile Acid Receptor 1 (1) Glutathione Reductase (GR) (1) HSP (3) IAP (1) IKK (1) Influenza Virus (3) Isotope-Labeled Compounds (6) JNK (3) Ligands for E3 Ligase (1) MDM-2/p53 (9) MicroRNA (3) MMP (3) mTOR (2) NF-κB (2) NO Synthase (2) p38 MAPK (1) PI3K (1) Potassium Channel (7) PROTACs (1) Reactive Oxygen Species (ROS) (7) Reference Standards (11) Small Interfering RNA (siRNA) (2) STAT (1) Survivin (1) TAM Receptor (1) Topoisomerase (3) Transmembrane Glycoprotein (1) VEGFR (8)
By Research Areas:	Cancer (63) Cardiovascular Disease (21) Infection (18) Inflammation/Immunology (20) Metabolic Disease (20) Neurological Disease (15)
Oligonucleotides:	siRNA drugs (2) siRNAs (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: HIF/HIF Prolyl-Hydroxylase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13426

Roxadustat 55+ Cited Publications FG-4592	HIF/HIF Prolyl-Hydroxylase Ferroptosis	Infection Cancer
Roxadustat is an orally active hypoxia-inducible factor prolyl-hydroxylase (PHD) inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin .

HY-16560

Camptothecin Maximum Cited Publications 68 Publications Verification Campathecin; (S)-(+)-Camptothecin; CPT	Topoisomerase ADC Payload MicroRNA Influenza Virus Apoptosis Fungal Antibiotic	Infection Cancer
Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC₅₀ of 679 nM . Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells .

HY-17412

Minocycline hydrochloride 60+ Cited Publications	Bacterial Antibiotic HIF/HIF Prolyl-Hydroxylase Apoptosis MDM-2/p53 Potassium Channel Calcium Channel	Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Minocycline hydrochloride is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline hydrochloride is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline hydrochloride shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline hydrochloride reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline hydrochloride inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect .

HY-B0239

Chloramphenicol 15+ Cited Publications	Antibiotic Bacterial HIF/HIF Prolyl-Hydroxylase VEGFR Autophagy Apoptosis Beclin1 JNK Akt MMP	Infection Cancer
Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascular endothelial growth factor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research .

HY-15836

BAY 87-2243 25+ Cited Publications	HIF/HIF Prolyl-Hydroxylase Ferroptosis	Cancer
BAY 87-2243 is a highly potent and selective hypoxia-inducible factor-1 (HIF-1) inhibitor.

HY-B0639

Amifostine 10+ Cited Publications WR2721	MDM-2/p53 HIF/HIF Prolyl-Hydroxylase	Cancer
Amifostine (WR2721) is a broad-spectrum cytoprotective agent and a radioprotector. Amifostine selectively protects normal tissues from damage caused by radiation and chemotherapy. Amifostine is potent hypoxia-inducible factor-α1 (HIF-α1) and p53 inducer. Amifostine protects cells from damage by scavenging oxygen-derived free radicals. Amifostine reduces renal toxicity and has antiangiogenic action .

HY-17608

Daprodustat 15+ Cited Publications GSK1278863	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
Daprodustat (GSK1278863) is an orally active hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor being developed for the treatment of anemia associated with chronic kidney disease.

HY-109057

Enarodustat 4 Publications Verification JTZ-951; SAL0951	HIF/HIF Prolyl-Hydroxylase	Metabolic Disease
Enarodustat is a potent and orally active hypoxia-inducible factor prolyl hydroxylase inhibitor, with an EC₅₀ of 0.22 μM. Enarodustat has the potential for renal anemia treatment.

HY-12654

Molidustat 5+ Cited Publications BAY 85-3934	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
Molidustat (BAY 85-3934) is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) with IC₅₀ values of 480 nM, 280 nM, and 450 nM for PHD1, PHD2, and PHD3, respectively. Molidustat can elevate the levels of circulating erythropoietin (EPO) to near-normal physiological ranges. Molidustat can be utilized in the research of renal anemia .

HY-17412A

Minocycline 60+ Cited Publications	Antibiotic Bacterial HIF/HIF Prolyl-Hydroxylase Apoptosis MDM-2/p53 Potassium Channel Calcium Channel	Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Minocycline is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect .

HY-18777

KC7F2 15+ Cited Publications	HIF/HIF Prolyl-Hydroxylase	Cancer
KC7F2 is a potent hypoxia inducible factor-1 (HIF-1) pathway inhibitor with an IC₅₀ of 20 μM in LN229-HRE-AP cells, and with potential as a cancer therapy agent .

HY-101277

Vadadustat 5+ Cited Publications PG-1016548; AKB-6548	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
Vadadustat (PG-1016548) is a titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor . Vadadustat is an erythropoiesis-stimulating agent and has the potential for anemia treatment in chronic kidney disease in vivo .

HY-106101

Echinomycin 10+ Cited Publications Quinomycin A; NSC-13502	HIF/HIF Prolyl-Hydroxylase Antibiotic Bacterial	Cancer
Echinomycin (Quinomycin A) is potent small-molecule and cell-permeable inhibitor of hypoxia-inducible factor-1 (HIF-1) DNA-binding activity. Echinomycin selectively inhibits the cancer stem cells (CSCs) with an IC₅₀ of 29.4 pM .

HY-12754

ML228 5+ Cited Publications CID-46742353	HIF/HIF Prolyl-Hydroxylase	Cancer
ML228 (CID-46742353) is a potent the Hypoxia Inducible Factor (HIF) pathway activator with EC₅₀ of 1 μM. ML228 potently activates HIF in vitro as well as its downstream target VEGF .

HY-111387

IDF-11774 5+ Cited Publications	HIF/HIF Prolyl-Hydroxylase	Cancer
IDF-11774 is a novel hypoxia-inducible factor α (HIFα)-1 inhibitor with an IC₅₀ of 3.65 μM.

HY-N3244

Moracin O 2 Publications Verification	HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS)	Neurological Disease Inflammation/Immunology Cancer
Moracin O is a 2-arylbenzofuran isolated from the Morus alba Linn. . Moracin O exhibits potent in vitro inhibitory activity against hypoxia-inducible factor (HIF-1). Moracin O reduces oxygen-glucose deprivation (OGD)-induced reactive oxygen species (ROS) production. Moracin O has neuroprotective and anti-inflammatory effects .

HY-110266

GN44028 5+ Cited Publications	HIF/HIF Prolyl-Hydroxylase	Cancer
GN44028 is a potent and orally active hypoxia inducible factor (HIF)-1α inhibitor, with an IC₅₀ of 14 nM. GN44028 inhibits hypoxia-induced HIF-1α transcriptional activity without suppressing HIF-1α mRNA expression, HIF-1α protein accumulation, or HIF-1α/HIF-1β heterodimerization. GN44028 can be used in the research of cancers .

HY-101023

MK-8617 3 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Inflammation/Immunology
MK-8617 is an orally active pan-inhibitor of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) with an IC₅₀ of 1 nM for PHD2.

HY-107553

Chetomin 1 Publications Verification	HSP Apoptosis	Cancer
Chetomin, an active component of Chaetomium globosum, is a heat shock protein 90/hypoxia-inducible factor 1 alpha (Hsp90/HIF1α) pathway inhibitor. Chetomin is a potent, nontoxic non-small cell lung cancer cancer stem cells (NSCLC CSC)-targeting molecule .

HY-159644

Casdatifan AB521	HIF/HIF Prolyl-Hydroxylase VEGFR	Cancer
Casdatifan (AB521) is an orally active and selective allosteric small-molecule inhibitor of hypoxia-inducible factor 2α (HIF-2α). Casdatifan inhibits pro-tumor gene transcription by blocking the heterodimerization of HIF-2α with ARNT, and significantly suppresses tumor growth in clear cell renal cell carcinoma (ccRCC) models either as a monotherapy or in combination with agents such as Zimberelimab (HY-P99109). Casdatifan is applicable for the research of ccRCC .

HY-112144

TP0463518 1 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Metabolic Disease Inflammation/Immunology
TP0463518 is an orally active, competitive pan-inhibitor of hypoxia-inducible factor prolyl hydroxylases PHD1/2/3. TP0463518 competitively inhibits human PHD1 (IC₅₀=18 nM), PHD2 (K_i=5.3 nM), and PHD3 (IC₅₀=63 nM), and targets monkey PHD2 with an IC₅₀ of 22 nM. TP0463518 inhibits PHD-catalyzed hydroxylation to stabilize HIFα, thereby upregulating erythropoietin (EPO) expression and enhancing intestinal iron absorption (such as increased DMT-1 and dCYTb expression), improving anemia. TP0463518 is mainly used for the research of renal anemia and inflammatory anemia .

HY-W016409

Ethyl 3,4-dihydroxybenzoate 1 Publications Verification Protocatechuic acid ethyl ester	HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) NO Synthase Autophagy Apoptosis	Metabolic Disease Cancer
Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema .

HY-17412R

Minocycline hydrochloride (Standard)	Reference Standards Antibiotic Bacterial HIF/HIF Prolyl-Hydroxylase Apoptosis MDM-2/p53 Potassium Channel Calcium Channel	Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Minocycline (hydrochloride) (Standard) is the analytical standard of Minocycline (hydrochloride). This product is intended for research and analytical applications. Minocycline hydrochloride is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline hydrochloride is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline hydrochloride shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline hydrochloride reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline hydrochloride inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect .

HY-P2324

Gramicidin A 1 Publications Verification	Bacterial HIF/HIF Prolyl-Hydroxylase Antibiotic	Infection Cancer
Gramicidin A is a peptide component of gramicidin, an antibiotic mixture originally isolated from B. brevis. Gramicidin A is a highly hydrophobic channel-forming ionophore that forms channels in model membranes that are permeable to monovalent cations. Gramicidin A induces degradation of hypoxia inducible factor 1 α (HIF-1α) .

HY-139287

M1002 2 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Cancer
M1002 is a **hypoxia-inducible factor-2 (HIF-2**) agonist, and can enhance the expression of HIF-2 target genes. M1002 shows synergy with prolyl-hydroxylase domain (PHD) inhibitors .

HY-108868

Mersalyl Salirgan; Salurin; Salyrgan	HIF/HIF Prolyl-Hydroxylase VEGFR	Metabolic Disease
Mersalyl (Salirgan) is a potent *vascular endothelial growth factor* (VEGF)** and hypoxia-inducible factor 1 (HIF-1) inducer. Mersalyl induces VEGF and ENO1 mRNA expression. Mersalyl shows diuresis effects .

HY-15672

FM19G11	HIF/HIF Prolyl-Hydroxylase	Neurological Disease Cancer
FM19G11 is a hypoxia-inducible factor-1-alpha (HIF-1α) inhibitor, and it inhibits hypoxia-induced luciferase activity with an IC₅₀ of 80 nM in HeLa cells. FM19G11 modulates other signaling pathways, including mTOR and PI3K/Akt/eNOS, when the HIF-1α pathway is inactivated under normoxic conditions .

HY-111547

M1001	HIF/HIF Prolyl-Hydroxylase	Cancer
M1001 is a weak **hypoxia-inducible factor-2α (HIF-2α) agonist. M1001 can bind to the HIF-2α PAS-B domain, with a K_d** of 667 nM. M1001 can be used in chronic kidney disease research .

HY-B2171A

Carubicin hydrochloride Carminomycin hydrochloride; Carminomicin I hydrochloride	Apoptosis	Infection Cancer
Carubicin hydrochloride is a microbially-derived compound. Carubicin hydrochloride is an effective inhibitor of VHL-defective (VHL−/−) CCRCC cell proliferation. Carubicin hydrochloride also induces apoptosis by a mechanism independent of p53 or hypoxia-inducible factor HIF2. Carubicin hydrochloride has the potential for the research of cancer diseases .

HY-B0639A

Amifostine trihydrate 10+ Cited Publications WR2721 trihydrate	MDM-2/p53 HIF/HIF Prolyl-Hydroxylase	Cancer
Amifostine trihydrate (WR2721 trihydrate) is a broad-spectrum cytoprotective agent and a radioprotector. Amifostine trihydrate selectively protects normal tissues from damage caused by radiation and chemotherapy. Amifostine trihydrate is potent hypoxia-inducible factor-α1 (HIF-α1) and p53 inducer. Amifostine trihydrate protects cells from damage by scavenging oxygen-derived free radicals. Amifostine trihydrate reduces renal toxicity and has antiangiogenic action .

HY-N0910

Notoginsenoside Ft1 1 Publications Verification	PI3K mTOR Akt Apoptosis p38 MAPK ERK Transmembrane Glycoprotein Glutathione Reductase (GR) Estrogen Receptor/ERR Calcium Channel Ferroptosis G protein-coupled Bile Acid Receptor 1 FXR	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Notoginsenoside Ft1 is an orally active bioactive saponin. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8 ⁺ T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular Ca ²⁺ accumulation, reduces cAMP levels by activating a signaling network mediated through P2Y₁₂ receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an FXR antagonist to combat obesity and insulin resistance .

HY-N3243

Moracin P 2 Publications Verification	HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS)	Neurological Disease Inflammation/Immunology Cancer
Moracin P is a 2-arylbenzofuran isolated from the Mori Cortex Radicis. Moracin P exhibits potent in vitro inhibitory activity against hypoxia-inducible factor (HIF-1). Moracin P reduces oxygen-glucose deprivation (OGD)-induced reactive oxygen species (ROS) production. Moracin P has neuroprotective and anti-inflammatory effects .

HY-147426

Zifcasiran ADS-007; ARO HIF2	Small Interfering RNA (siRNA) HIF/HIF Prolyl-Hydroxylase	Cancer
Zifcasiran (ADS-007; ARO HIF2) is an siRNA synthetic double-stranded RNAi trigger. Zifcasiran sodium selectively target hypoxia-inducible factor-2α (HIF2α) interrupting downstream pro-oncogenic signaling in clear cell renal cell carcinoma (ccRCC). Zifcasiran sodium engages the cell's RNAi machinery to target HIF2α (EPAS1) mRNA for degradation, thereby reducing the amount of free HIF2α mRNA available for translation .

HY-168641

PROTAC HIF-1α degrader-1	PROTACs Apoptosis HIF/HIF Prolyl-Hydroxylase	Cancer
PROTAC HIF-1α degrader-1 (compound V2) is a potent hypoxia-inducible factor-1α (HIF-1α) PROTAC degrader with an IC₅₀ value of 7.54 µM. PROTAC HIF-1α degrader-1 shows anti-proliferative activity. PROTAC HIF-1α degrader-1 decreases the HIF-1α protein expression. PROTAC HIF-1α degrader-1 induces apoptosis. (Pink: ligand for target protein (HY-111387); black: linker (HY-W013731); Blue: E3 ligase ligand (HY-112078)) .

HY-16187

EL-102	HIF/HIF Prolyl-Hydroxylase Apoptosis	Cancer
EL-102 is a hypoxia-induced factor 1 (Hif1α) inhibitor. EL-102 induces apoptosis, inhibits tubulin polymerisation and shows activities against prostate cancer. EL-102 can be used for the research of cancer .

HY-B0239R

Chloramphenicol (Standard)	Reference Standards Antibiotic Bacterial HIF/HIF Prolyl-Hydroxylase VEGFR Autophagy Apoptosis Beclin1 JNK Akt MMP	Infection Cancer
Chloramphenicol (Standard) is the analytical standard of Chloramphenicol. This product is intended for research and analytical applications. Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascular endothelial growth factor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research .

HY-P10426

cyclo(CLLFVY)	HIF/HIF Prolyl-Hydroxylase VEGFR	Cancer
cyclo(CLLFVY) is an inhibitor for **hypoxia inducible factor-1 (HIF-1), with IC₅₀** of 19 μM (in U2OS) and 16 μM (in MCF-7). cyclo(CLLFVY) binds to the PAS-B domain of HIF-1α, inhibits HIF-1 dimerization and transcriptional activity. cyclo(CLLFVY) downregulates the expression of hypoxia response genes, such as VEGF and CAIX, exhibits antitumor against the HIF-1 associated cancers .

HY-146144

HIF-IN-1	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-IN-1 (Compound 3c) is a hypoxia-inducible factor (HIF)-1 inhibitor. HIF-IN-1 suppresses HIF-1α protein accumulation without affecting the levels of HIF-1α mRNA. HIF-IN-1 shows no obvious cytotoxicity .

HY-168533

ZG-2305	HIF/HIF Prolyl-Hydroxylase	Metabolic Disease
ZG-2305 is a potent, orally active and selective factor inhibiting hypoxia-inducible factor (FIH) inhibitor with K_i values of 79.6, 2786 nM for FIH, PHD2, respectively. ZG-2305 increases the expression of EGLN3 gene. ZG-2305 decreases the cellular triglycerides levels and reduces lipid accumulation. ZG-2305 has the potential for the research of obesity and fatty liver disease .

HY-N6905

Acetylarenobufagin	HIF/HIF Prolyl-Hydroxylase	Cancer
Acetylarenobufagin is a steroidal hypoxia inducible factor-1 (HIF-I) modulator .

HY-136748

HIF-2α-IN-4 1 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-4 is a potent inhibitor of hypoxia inducible factor-2α (HIF-2α) translation, with an IC₅₀ of 5 μM. HIF-2α-IN-4 decreases both constitutive and hypoxia-induced HIF-2α protein expression. HIF-2α-IN-4 links its 5'UTR iron-responsive element to oxygen sensing .

HY-N3001

Isolinderalactone 1 Publications Verification	STAT VEGFR Bcl-2 Family Survivin IAP NF-κB Apoptosis Caspase	Neurological Disease Inflammation/Immunology Cancer
Isolinderalactone is a sesquiterpene that exhibits anti-cancer, anti-inflammatory, and neuroprotective effects. Isolinderalactone inhibits VEGF expression and tyrosine phosphorylation of VEGFR2. Isolinderalactone decreases viability and induces apoptosis in U-87 glioblastoma (GBM) cells and colorectal cancer (CRC) cells. Isolinderalactone induces G2/M phase cell cycle arrest, ROS generation, pJNK/p38 MAPK activation, in colorectal cancer (CRC) cells. Isolinderalactone blocks LPS (HY-D1056)-induced NF-κB activation while activating Nrf2-HMOX1 signaling in RAW264.7 macrophages. Isolinderalactone improves cognitive dysfunction in APP/PS1 mice. Isolinderalactone can be used for the study of Glioblastoma multiforme (GBM), colorectal cancer, Alzheimer’s disease and acute lung injury .

HY-P1888

HIF-1 alpha (556-574)	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
HIF-1 alpha (556-574) is a short hypoxia-inducible factor-1 (HIF-1) 19 residues fragment. HIF-1 functions as master regulator of response to oxygen homeostasis .

HY-108697A

(Rac)-PT2399	HIF/HIF Prolyl-Hydroxylase	Cancer
(Rac)-PT2399 (Compound 10e), the racemate of PT2399, acts as a potent and specific hypoxia-inducible factor 2a (HIF-2α) inhibitor with an IC₅₀ of 0.01 μM .

HY-13426S

Roxadustat-d5	HIF/HIF Prolyl-Hydroxylase Ferroptosis	Cancer
Roxadustat-d₅ is deuterium labeled Roxadustat. Roxadustat is an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin .

HY-16560S

Camptothecin-d5 Campathecin-d₅; (S)-(+)-Camptothecin-d₅; CPT-d₅	Isotope-Labeled Compounds Topoisomerase ADC Payload MicroRNA Influenza Virus Apoptosis Fungal Antibiotic	Infection Cancer
Camptothecin-d₅ is the deuterium labeled Camptothecin. Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC₅₀ of 679 nM . Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells .

HY-17412AS

Minocycline-d6	Isotope-Labeled Compounds Antibiotic Bacterial HIF/HIF Prolyl-Hydroxylase Apoptosis MDM-2/p53 Potassium Channel Calcium Channel	Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Minocycline-d₆ is deuterium labeled Minocycline (HY-17412A). Minocycline is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect .

HY-P10222

Cyclo(CRLLIF)	HIF/HIF Prolyl-Hydroxylase	Cancer
Cyclo CRLLIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains K_D of 14.5 and 10.2 μM, respectively .

HY-147426A

Zifcasiran sodium ADS-007 sodium; ARO HIF2 sodium	Small Interfering RNA (siRNA) HIF/HIF Prolyl-Hydroxylase	Cancer
Zifcasiran (ADS-007) sodium is an siRNA synthetic double-stranded RNAi trigger. Zifcasiran sodium selectively target hypoxia-inducible factor-2α (HIF2α) interrupting downstream pro-oncogenic signaling in clear cell renal cell carcinoma (ccRCC). Zifcasiran sodium engages the cell's RNAi machinery to target HIF2α (EPAS1) mRNA for degradation, thereby reducing the amount of free HIF2α mRNA available for translation .

HY-18370

HIF-2α-IN-3	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-3, an allosteric inhibitor of **hypoxia inducible factor-2α (HIF-2α), exhibits an IC₅₀ of 0.4 µM and a K_D** of 1.1 µM. Anticancer agent .

Cat. No.	Product Name

HY-L045

Oxygen Sensing Compound Library

4,029 compounds

Oxygen homeostasis regulation is the most fundamental cellular process for adjusting physiological oxygen variations, and its irregularity leads to various human diseases, including cancer. Hypoxia is closely associated with cancer development, and hypoxia/oxygen-sensing signaling plays critical roles in the modulation of cancer progression.

Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. A variety of HF-1 target genes have been identified thus far which encode proteins that play key roles in critical developmental and physiological processes including angiogenesis/vascular remodeling, erythropoiesis, glucose transport, glycolysis, iron transport, and cell proliferation/survival.

HIF-1 is a heterodimeric transcription factor consisting of a constitutively expressed β-subunit and an oxygen-regulated α-subunit. The unique feature of HIF-1 is the regulation of HIF-1α expression and activity based upon the cellular O₂ concentration. Under normoxic conditions, hydroxylation of HIF-1α on these different proline residues is essential for HIF proteolytic degradation by promoting interaction with the von Hippel-Lindau tumor-suppressor protein (pVHL) through hydrogen bonding to the hydroxyproline-binding pocket in the pVHL β-domain. As oxygen levels decrease, hydroxylation of HIF decreases; HIF-1α then no longer binds pVHL, and becomes stabilized, allowing more of the protein to translocate to the cell’s nucleus, where it acts as a transcription factor, upregulating (often within minutes) the production of proteins that stimulate blood perfusion in tissues and thus tissue oxygenation.

MCE offers a unique collection of 4,029 oxygen sensing related compounds targeting HIF/HIF Prolyl-Hydroxylase, MAPK/ERK, PI3K/AKT signaling pathways, etc. MCE Oxygen Sensing Compound Library is a useful tool to study hypoxia, oxidative stress and discover new anti-cancer drugs.

Cat. No.	Product Name	Target	Research Area

HY-P2324

Gramicidin A 1 Publications Verification	Bacterial HIF/HIF Prolyl-Hydroxylase Antibiotic	Infection Cancer
Gramicidin A is a peptide component of gramicidin, an antibiotic mixture originally isolated from B. brevis. Gramicidin A is a highly hydrophobic channel-forming ionophore that forms channels in model membranes that are permeable to monovalent cations. Gramicidin A induces degradation of hypoxia inducible factor 1 α (HIF-1α) .

HY-P10426

cyclo(CLLFVY)	HIF/HIF Prolyl-Hydroxylase VEGFR	Cancer
cyclo(CLLFVY) is an inhibitor for **hypoxia inducible factor-1 (HIF-1), with IC₅₀** of 19 μM (in U2OS) and 16 μM (in MCF-7). cyclo(CLLFVY) binds to the PAS-B domain of HIF-1α, inhibits HIF-1 dimerization and transcriptional activity. cyclo(CLLFVY) downregulates the expression of hypoxia response genes, such as VEGF and CAIX, exhibits antitumor against the HIF-1 associated cancers .

HY-P1888

HIF-1 alpha (556-574)	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
HIF-1 alpha (556-574) is a short hypoxia-inducible factor-1 (HIF-1) 19 residues fragment. HIF-1 functions as master regulator of response to oxygen homeostasis .

HY-P10222

Cyclo(CRLLIF)	HIF/HIF Prolyl-Hydroxylase	Cancer
Cyclo CRLLIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains K_D of 14.5 and 10.2 μM, respectively .

HY-P10223

Cyclo(CRVIIF)	HIF/HIF Prolyl-Hydroxylase	Cancer
Cyclo CRVIIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains K_D of 65 and 123 μM, respectively .

HY-P1888A

HIF-1 alpha (556-574) TFA	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
HIF-1 alpha (556-574) TFA is a short hypoxia-inducible factor-1 (HIF-1) 19 residues fragment. HIF-1 functions as master regulator of response to oxygen homeostasis .

HY-P2324A

Gramicidin A TFA	Antibiotic Bacterial	Infection
Gramicidin A (TFA) is a peptide component of gramicidin, an antibiotic mixture originally isolated from B. brevis. Gramicidin A (TFA) is a highly hydrophobic channel-forming ionophore that forms channels in model membranes that are permeable to monovalent cations. Gramicidin A (TFA) induces degradation of hypoxia inducible factor 1 α (HIF-1α) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-16560

Camptothecin Maximum Cited Publications 68 Publications Verification Campathecin; (S)-(+)-Camptothecin; CPT	Infection Alkaloids Classification of Application Fields Quinoline Alkaloids Camptotheca acuminata Decne. Nyssaceae Plants Disease Research Fields	Topoisomerase ADC Payload MicroRNA Influenza Virus Apoptosis Fungal Antibiotic
Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC₅₀ of 679 nM . Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells .

HY-B0239

Chloramphenicol 15+ Cited Publications	Structural Classification Classification of Application Fields Anti-aging Antibacterial Disease Research Endogenous metabolite Other Antibiotics Infection Human Gut Microbiota Metabolites Plant Cell Culture Microorganisms Antibiotics Resistance Selection Animal Husbandry Anticancer Disease Research Fields Source Classification Cancer	Antibiotic Bacterial HIF/HIF Prolyl-Hydroxylase VEGFR Autophagy Apoptosis Beclin1 JNK Akt MMP
Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascular endothelial growth factor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research .

HY-N3244

Moracin O 2 Publications Verification	Neurological Disease Classification of Application Fields Phenols Polyphenols Plants Moraceae Inflammation/Immunology Disease Research Fields Morus alba Linn. Source Classification	HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS)
Moracin O is a 2-arylbenzofuran isolated from the Morus alba Linn. . Moracin O exhibits potent in vitro inhibitory activity against hypoxia-inducible factor (HIF-1). Moracin O reduces oxygen-glucose deprivation (OGD)-induced reactive oxygen species (ROS) production. Moracin O has neuroprotective and anti-inflammatory effects .

HY-W016409

Ethyl 3,4-dihydroxybenzoate 1 Publications Verification Protocatechuic acid ethyl ester	Arachis hypogaea L. Classification of Application Fields Leguminosae Phenols Polyphenols Metabolic Disease Plants Disease Research Fields Source Classification	HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) NO Synthase Autophagy Apoptosis
Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema .

HY-B2171A

Carubicin hydrochloride Carminomycin hydrochloride; Carminomicin I hydrochloride	Infection Quinones Microorganisms Classification of Application Fields Anthraquinones Phenols Polyphenols Disease Research Fields Source Classification	Apoptosis
Carubicin hydrochloride is a microbially-derived compound. Carubicin hydrochloride is an effective inhibitor of VHL-defective (VHL−/−) CCRCC cell proliferation. Carubicin hydrochloride also induces apoptosis by a mechanism independent of p53 or hypoxia-inducible factor HIF2. Carubicin hydrochloride has the potential for the research of cancer diseases .

HY-N0910

Notoginsenoside Ft1 1 Publications Verification	Triterpenes Structural Classification Panax notoginseng (Burkill) F. H. Chen ex C. H. Chow Classification of Application Fields Terpenoids Other Diseases Plants Disease Research Fields Araliaceae Source Classification	PI3K mTOR Akt Apoptosis p38 MAPK ERK Transmembrane Glycoprotein Glutathione Reductase (GR) Estrogen Receptor/ERR Calcium Channel Ferroptosis G protein-coupled Bile Acid Receptor 1 FXR
Notoginsenoside Ft1 is an orally active bioactive saponin. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8 ⁺ T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular Ca ²⁺ accumulation, reduces cAMP levels by activating a signaling network mediated through P2Y₁₂ receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an FXR antagonist to combat obesity and insulin resistance .

HY-N3243

Moracin P 2 Publications Verification	other families Neurological Disease Classification of Application Fields Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields Source Classification	HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS)
Moracin P is a 2-arylbenzofuran isolated from the Mori Cortex Radicis. Moracin P exhibits potent in vitro inhibitory activity against hypoxia-inducible factor (HIF-1). Moracin P reduces oxygen-glucose deprivation (OGD)-induced reactive oxygen species (ROS) production. Moracin P has neuroprotective and anti-inflammatory effects .

HY-B0239R

Chloramphenicol (Standard)	Structural Classification Antibacterial Disease Research Endogenous metabolite Other Antibiotics Human Gut Microbiota Metabolites Plant Cell Culture Microorganisms Antibiotics Resistance Selection Animal Husbandry Anticancer Source Classification	Reference Standards Antibiotic Bacterial HIF/HIF Prolyl-Hydroxylase VEGFR Autophagy Apoptosis Beclin1 JNK Akt MMP
Chloramphenicol (Standard) is the analytical standard of Chloramphenicol. This product is intended for research and analytical applications. Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascular endothelial growth factor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research .

HY-N6905

Acetylarenobufagin	Classification of Application Fields Animals Disease Research Fields Steroids Cancer Source Classification	HIF/HIF Prolyl-Hydroxylase
Acetylarenobufagin is a steroidal hypoxia inducible factor-1 (HIF-I) modulator .

HY-N3001

Isolinderalactone 1 Publications Verification	Classification of Application Fields Terpenoids Sesquiterpenes Plants Lauraceae Lindera aggregata (Sims) Kosterm. Disease Research Fields Source Classification Cancer	STAT VEGFR Bcl-2 Family Survivin IAP NF-κB Apoptosis Caspase
Isolinderalactone is a sesquiterpene that exhibits anti-cancer, anti-inflammatory, and neuroprotective effects. Isolinderalactone inhibits VEGF expression and tyrosine phosphorylation of VEGFR2. Isolinderalactone decreases viability and induces apoptosis in U-87 glioblastoma (GBM) cells and colorectal cancer (CRC) cells. Isolinderalactone induces G2/M phase cell cycle arrest, ROS generation, pJNK/p38 MAPK activation, in colorectal cancer (CRC) cells. Isolinderalactone blocks LPS (HY-D1056)-induced NF-κB activation while activating Nrf2-HMOX1 signaling in RAW264.7 macrophages. Isolinderalactone improves cognitive dysfunction in APP/PS1 mice. Isolinderalactone can be used for the study of Glioblastoma multiforme (GBM), colorectal cancer, Alzheimer’s disease and acute lung injury .

HY-B2171

Carubicin Carminomycin; Carminomicin I	Infection Quinones Microorganisms Classification of Application Fields Anthraquinones Phenols Polyphenols Disease Research Fields Source Classification	Apoptosis
Carubicin (Carminomycin) is a microbially-derived compound. Carubicin is an effective inhibitor of VHL-defective (VHL−/−) CCRCC cell proliferation. Carubicin also induces apoptosis by a mechanism independent of p53 or hypoxia-inducible factor HIF2. Carubicin has the potential for the research of cancer diseases .

HY-16560R

Camptothecin (Standard) Campathecin (Standard); (S)-(+)-Camptothecin (Standard); CPT (Standard)	Alkaloids Structural Classification Quinoline Alkaloids Camptotheca acuminata Decne. Nyssaceae Plants	Reference Standards Topoisomerase ADC Payload MicroRNA Influenza Virus Apoptosis Fungal Antibiotic
Camptothecin (Standard) (Campathecin (Standard)) is the analytical standard of Camptothecin (HY-16560). This product is intended for research and analytical applications. Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC₅₀ of 679 nM. Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells.

HY-N12041

Axl-IN-16	Natural Products Microorganisms Source Classification	TAM Receptor HIF/HIF Prolyl-Hydroxylase
Axl-IN-16 is a dual inhibitor of Axl/HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl-IN-16 inhibits hypoxia-inducible factor activity and receptor tyrosine kinase expression .

HY-N10330

7-Hydroxyneolamellarin A	Animals Phenols Source Classification	HIF/HIF Prolyl-Hydroxylase VEGFR
7-Hydroxyneolamellarin A is a natural product that could be derived from sponge Dendrilla nigra. 7-Hydroxyneolamellarin A is a potent hypoxia-inducible factor-1α (HIF-1α) inhibitor. 7-Hydroxyneolamellarin A attenuates the accumulation of hypoxia-inducible factor-1α (HIF-1α) protein and inhibits vascular epidermal growth factor (VEGF) transcriptional activity. 7-Hydroxyneolamellarin A can be used in research of cancer .

HY-W016409R

Ethyl 3,4-dihydroxybenzoate (Standard) Protocatechuic acid ethyl ester (Standard)	Structural Classification Arachis hypogaea L. Leguminosae Phenols Polyphenols Plants Source Classification	Reference Standards HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) NO Synthase Autophagy Apoptosis
Ethyl 3,4-dihydroxybenzoate (Standard) (Protocatechuic acid ethyl ester (Standard)) is the analytical standard of Ethyl 3,4-dihydroxybenzoate (HY-W016409). This product is intended for research and analytical applications. Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema .

Species:	Human (3)
Tag:	His (3)
Source:	E. coli (3)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P74888

	HIF-1 alpha Protein, Human (His) 4 Publications Verification hypoxia-inducible factor 1-alpha; HIF-1-alpha; BHLHE78; HIF1A; MOP1; PASD8	Human	E. coli
	HIF-1 alpha is a key protein that responds to low oxygen levels. HIF-1 alpha Protein, Human (His) is the recombinant human-derived HIF-1 alpha protein, expressed by E. coli , with N-His labeled tag.

HY-P706012

	EGLN1 Protein, Human (His) hypoxia-inducible factor prolyl hydroxylase 2 (HIF-PH2; HIF-prolyl hydroxylase 2; HPH-2); Prolyl hydroxylase domain-containing protein 2 (PHD2); SM-20; C1orf12; PNAS-118; PNAS-137	Human	E. coli

HY-P703327

	EGLN1 Protein, Human (246a.a, His) C1orf12; PNAS-118; PNAS-137; Egl nine homolog 1; hypoxia-inducible factor prolyl hydroxylase 2 (HIF-PH2; HIF-prolyl hydroxylase 2; HPH-2); Prolyl hydroxylase domain-containing protein 2 (PHD2)	Human	E. coli
	EGLN1 Protein, Human (246a.a, His) is the recombinant human-derived EGLN1, expressed by E. coli , with His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-13426S

Roxadustat-d5
Roxadustat-d₅ is deuterium labeled Roxadustat. Roxadustat is an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin .

HY-16560S

Camptothecin-d5

Camptothecin-d₅ is the deuterium labeled Camptothecin. Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC₅₀ of 679 nM . Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells .

HY-17412AS

Minocycline-d6

Minocycline-d₆ is deuterium labeled Minocycline (HY-17412A). Minocycline is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect .

HY-101277S1

Vadadustat-13C6
Vadadustat- ¹³C₆ (PG-1016548- ¹³C₆) is ¹³C labeled Vadadustat. Vadadustat (PG-1016548) is a titratable, oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor . Vadadustat is an erythropoiesis-stimulating agent and has the potential for anemia treatment in chronic kidney disease in vivo .

HY-17412S1

Minocycline-d6 sulfate

Minocycline-d₆ sulfate is deuterated labeled Minocycline (HY-17412A). Minocycline is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect .

HY-17412S

Minocycline-d6 hydrochloride

Minocycline-d₆ hydrochloride is deuterated labeled Minocycline hydrochloride (HY-17412). Minocycline hydrochloride is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline hydrochloride is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline hydrochloride shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline hydrochloride reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline hydrochloride inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect .

HY-B0239S2

Threo-Chloramphenicol-d6

Threo-Chloramphenicol-d₆ is the deuterium labeled Chloramphenicol . Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascular endothelial growth factor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research .

HY-W654013

Minocycline-d7

Minocycline-d₇ is deuterium labeled Minocycline. Minocycline is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect .

HY-W778057

Ethyl 3,4-Dihydroxybenzoate-13C3

Ethyl 3,4-Dihydroxybenzoate- ¹³C₃ (Protocatechuic acid ethyl ester- ¹³C₃) is the ¹³C-labeled Ethyl 3,4-dihydroxybenzoate (HY-W016409). Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema .

Host:	Mouse (2) Rabbit (7)
Reactivity:	Human (9) Rat (7) Mouse (7) Hamster (2)
Application:	IHC-P (8) ICC/IF (5) IF-Tissue (1) IP (2) IHC-F (2) WB (9) FC (4) ELISA (1)
Isotype:	IgG (7)
Conjugation:	Non-conjugated (9)
Clonality:	Polyclonal (1) Monoclonal (6) Recombinant (3)
Modification:	Unmodified (7)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P80705

	HIF1 beta Antibody (YA385) ARNT; BHLHE2; Aryl hydrocarbon receptor nuclear translocator; ARNT protein; Class E basic helix-loop-helix protein 2; bHLHe2; Dioxin receptor; nuclear translocator; hypoxia-inducible factor 1-beta; HIF-1-beta; HIF1-beta	WB, IHC-P	Human, Mouse, Rat, Hamster
	HIF1 beta Antibody (YA385) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HIF1 beta.

HY-P85750

	HIF1 beta Antibody (YA5442) ARNT; BHLHE2; Aryl hydrocarbon receptor nuclear translocator; ARNT protein; Class E basic helix-loop-helix protein 2; bHLHe2; Dioxin receptor, nuclear translocator; hypoxia-inducible factor 1-beta; HIF-1-beta; HIF1-beta	WB, IHC-P, ICC/IF	Human, Mouse, Rat
	HIF1 beta Antibody (YA5442) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to HIF1 beta.

HY-P80705A

	HIF1 beta Antibody (YA385)(PBS only) ARNT; BHLHE2; Aryl hydrocarbon receptor nuclear translocator; ARNT protein; Class E basic helix-loop-helix protein 2; bHLHe2; Dioxin receptor; nuclear translocator; hypoxia-inducible factor 1-beta; HIF-1-beta; HIF1-beta	WB, IHC-P	Human, Mouse, Rat, Hamster
	HIF1 beta Antibody (YA385) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HIF1 beta.

HY-P85711

	HIF1 alpha Antibody (YA5403) hypoxia-inducible factor 1-alpha; HIF-1-alpha; HIF1-alpha; ARNT-interacting protein; Basic-helix-loop-helix-PAS protein MOP1; Class E basic helix-loop-helix protein 78; bHLHe78; Member of PAS protein 1; PAS domain-containing protein 8;	IHC-P, WB	Human, Mouse, Rat
	HIF1 alpha Antibody (YA5403) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to HIF1 alpha.

HY-P80704

	HIF1 alpha Antibody 5+ Cited Publications HIF1A; BHLHE78; MOP1; PASD8; hypoxia-inducible factor 1-alpha; HIF-1-alpha; HIF1-alpha; ARNT-interacting protein; Basic-helix-loop-helix-PAS protein MOP1; Class E basic helix-loop-helix protein 78; bHLHe78; Member of PAS protein 1; PAS doma	WB, ICC/IF, ELISA	Human, Mouse, Rat
	HIF1 alpha Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to HIF1 alpha.

HY-P85201

	HIF1 alpha Antibody (YA4893) HIF1A; BHLHE78; MOP1; PASD8; hypoxia-inducible factor 1-alpha; HIF-1-alpha; HIF1-alpha; ARNT-interacting protein; Basic-helix-loop-helix-PAS protein MOP1; Class E basic helix-loop-helix protein 78; bHLHe78; Member of PAS protein 1; PAS doma	WB, IHC-P, IHC-F, ICC/IF, IP, FC	Human
	HIF1 alpha Antibody (YA4893) is a Rabbit-derived and non-conjugated monoclonal antibody, targeting to HIF1 alpha.

HY-P81153

	HIF-2 alpha Antibody (YA3517) Basic helix loop helix PAS protein MOP2; Basic-helix-loop-helix-PAS protein MOP2; bHLHe73; Class E basic helix-loop-helix protein 73; ECYT4; Endothelial PAS domain containing protein 1; Endothelial pas domain protein 1; Endothelial PAS domain-containing protein 1; EPAS 1; EPAS-1; EPAS1; EPAS1_HUMAN; HIF 1 alpha like factor; HIF-1-alpha-like factor; HIF-2-alpha; HIF2-alpha; HIF2A; HLF; hypoxia inducible factor 2 alpha; hypoxia inducible factor 2 alpha subunit; hypoxia-inducible factor 2-alpha; Member of PAS protein 2; Member of pas superfamily 2; MOP 2; MOP2; PAS domain-containing protein 2; PASD2.	WB, IHC-P, FC	Human, Mouse, Rat
	HIF-2 alpha Antibody (YA3517) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HIF-2 alpha.

HY-P85201A

	HIF1 alpha Antibody (YA4893)(PBS only) HIF1A; BHLHE78; MOP1; PASD8; hypoxia-inducible factor 1-alpha; HIF-1-alpha; HIF1-alpha; ARNT-interacting protein; Basic-helix-loop-helix-PAS protein MOP1; Class E basic helix-loop-helix protein 78; bHLHe78; Member of PAS protein 1; PAS doma	WB, IHC-P, IHC-F, ICC/IF, IP, FC	Human
	HIF1 alpha Antibody (YA4893) is a Rabbit-derived and non-conjugated monoclonal antibody, targeting to HIF1 alpha.

HY-P87578

	PHD1 Antibody (YA7262) DKFZp434E026 antibody; Egl nine homolog 2 antibody; EGLN 2 antibody; EIT 6 antibody; Estrogen-induced tag 6 antibody; HIF P4H 1 antibody; HIF prolyl hydroxylase 1 antibody; HIF-PH1 antibody; HIF-prolyl hydroxylase 1 antibody; HIFPH 1 antibody; HPH-3 antibody; HPH3 antibody; hypoxia-inducible factor prolyl hydroxylase 1 antibody; P4H1 antibody; PHD 1 antibody; prolyl hydroxylase domain containing protein 1 antibody	WB, IHC-P, ICC/IF, FC, IF-Tissue	Human, Mouse, Rat
	PHD1 Antibody (YA7262) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PHD1.